-
-
-
-
-
-
-
INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA
-
-
-
-
-
-
-
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
-
-
-
-
-
-
-
INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company
-
-
-
-
-
-
-
INVO Bioscience Announces Closing of $4.5 Million Public Offering
-
-
-
-
-
-
-
INVO Reports Fourth Quarter and Full Year 2022 Financial Results
-
-
-
-
-
-
-
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.03%
-
-
-
-
-
-
-
INVO Bioscience (INVO) Regains Full Commercialization Rights in the US
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

